SGLT2 inhibitors and dulaglutide are associated with comparable risk for dementia; however, it is uncertain whether these findings generalize to newer GLP-1 RAs.

Researchers have found that people who take a type of type 2 diabetes drugs SGLT2 inhibitors have a significantly lower risk ...

Sodium-glucose cotransporter-2 (SGLT2) inhibitors, a class of diabetes drugs also known as gliflozins, could lower the risk ...

SGLT2 inhibitors, a class of diabetes drugs, may reduce the risk of Alzheimer’s, vascular dementia, and Parkinson’s disease, ...

For people having surgery unrelated to their hearts, new guidelines detail how to manage heart and stroke risks before, ...

Scientists found a 22 percent lower risk of any dementia and Parkinson's among a group taking SGLT2 inhibitors for type 2 ...

A class of drugs for diabetes may be associated with a lower risk of dementia and Parkinson's disease, according to a study ...

Noninvasive, low‐level tragus stimulation modestly reduced blood pressure (BP) in relatively healthy people with grade 1 ...

New research shows diabetes drugs may significantly reduce the risk of dementia, Alzheimer's, and Parkinson’s disease.

According to a new study, certain diabetes medications may significantly reduce this risk. These drugs, called gliflozins or ...

In patients with type 2 diabetes, GLP-1 receptor agonists and SGLT2 inhibitors have similar kidney and cardiovascular outcomes. Similar kidney and cardiovascular outcomes are found with glucagon-like ...